Lisanti Capital Growth LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) during the third quarter by 52.3%, as stated in the most recent Form 13F filing that Apellis Pharmaceuticals, Inc. made with the Securities and Exchange Commission. The institutional investor now has a total of 197,290 shares of ownership in the company after purchasing an additional 67,782 shares during the quarter. This brings the total number of company ownership shares to 197,290. Lisanti Capital Growth LLC’s stake in Apellis Pharmaceuticals places it in 12th place among its holdings and accounts for 1.8% of the company’s total assets. Lisanti Capital Growth LLC had 0.18% of the shares of Apellis Pharmaceuticals, which had a market value of $13,475,000 at the end of the most recent reporting period.
Recent events have resulted in institutional investors and other hedge funds reevaluating the positions they had previously held in the company and making appropriate adjustments. The value of US Bancorp DE’s holdings in Apellis Pharmaceuticals increased by 391.2 percent over the first three months of 2018. US Bancorp DE now has 1,110 shares, valued at $56,000, after purchasing an additional 884 shares during the preceding quarter. US Bancorp, Inc purchased these shares. China Universal Asset Management Co. Ltd. acquired a new position in Apellis Pharmaceuticals shares during the third quarter, estimated to be worth approximately $70,000. Coston McIsaac & Partners spent approximately $136,000 during the third quarter to acquire a new holding in Apellis Pharmaceuticals. This transaction took place during the company’s third fiscal quarter. The Great West Life Assurance Company of Canada increased its ownership stake in Apellis Pharmaceuticals by 15.5% during the first three months of 2018. Great West Life Assurance Company now holds 3,734 shares of the company’s stock following the acquisition of an additional 500 shares during the most recent quarter. Each share of the company’s stock is currently valued at $202,000.
Last but not least, during the first quarter of 2018, Mackenzie Financial Corporation put $206,000 into Apellis Pharmaceuticals. This investment should not be considered the least important. To the tune of 87.26 percent, the company’s stock is owned by institutional investors who have invested in the company.
There has been a significant increase in the number of places where investors can access analyst reports on the APLS stock. Apellis Pharmaceuticals was downgraded by Wells Fargo & Company in a research report that was published on January 2. The company went from having an “overweight” rating to having an “equal weight” rating. In addition, the brokerage firm lowered its target price for the stock, which it had previously set at $83, to $58.00. Jefferies Financial Group lowered their target price for Apellis Pharmaceuticals from $70.00 to $40.00 in a research report published on Thursday, November 10.
Additionally, they changed their rating for the company from “buy” to “hold.” In addition to this, they decreased their price objective for the stock from $70.00 to $40.00. The Credit Suisse Group assigned a “neutral” rating to Apellis Pharmaceuticals in a report distributed on Tuesday, November 8. Additionally, the firm lowered its price objective for the company from $45.00 to $43.00. The price target had been previously set at $45.00. Wedbush Investment Research decreased its price objective on Apellis Pharmaceuticals from $59.00 to $47.00 in a report made public on November 8.
Last but not least, on October 18, Raymond James published a research report stating that their price objective for Apellis Pharmaceuticals had been raised from $113.00 to $123.00 and that they had a “strong-buy” rating for the company’s shares. The report also stated they had a “buy” rating for the company’s shares. One analyst suggests selling the stock, four analysts suggest holding the stock, seven analysts suggest buying the stock, and one analyst suggests a strong buy of the stock. The current average rating for Apellis Pharmaceuticals is “Moderate Buy,” and the average price objective for the company is $71.23, according to information provided by Bloomberg.
On Monday morning, the price of a share of APLS stock was $52.56 when trading got underway. During the last year, the price of Apellis Pharmaceuticals, Inc. fluctuated between $33.32 and $70.00 at various points. The price has been as low as $33.32 and as high as $70.00. There is a 0.30 debt-to-equity ratio, a 6.69 quick ratio to the current ratio, and a 7.21 current ratio to the quick ratio. The ratio of the current ratio to the quick ratio is the highest. The company has seen a moving average of $49.50 over the past 50 days, and the moving average over the last 200 days is $55.50.
On November 7, Apellis Pharmaceuticals (NASDAQ: APLS) made available to the public its report regarding the performance of the company. The actual earnings per share generated by the company for the period came in at $1.75, which was $0.27 less than the consensus forecast of $1.48 per share. The analysts’ estimates for the company’s quarterly sales were $19.82 million, but the actual sales for the quarter were $22.06 million. This result was significantly better than predicted. Apellis Pharmaceuticals had a return on equity of 194.70%, and the company had a negative net margin of 560.92%. The projections of seasoned professionals in the relevant field indicate that Apellis Pharmaceuticals, Inc. will report a $6.23 per share loss during the current fiscal year.
Additionally, on November 3, Adam J. Townsend, employed by Apellis Pharmaceuticals, sold 5,000 shares of the company’s stock. The amount of stock sold came to a total of $292,700.00, and the price of $58.54 per share was determined to be the average selling price. After the completion of the transaction, the company insider now directly owns 42,907 shares of the company’s stock. Based on the current stock price, these shares are worth $2,511,775.78. On the Securities and Exchange Commission website, you can find a copy of the legal document that provides a more in-depth description of the sale. The document in question describes the sale of the asset.
Additionally, on November 3, Adam J. Townsend, employed by Apellis Pharmaceuticals, sold 5,000 shares of the company’s stock. The amount of stock sold came to a total of $292,700.00, and the price of $58.54 per share was determined to be the average selling price. After the completion of the transaction, the company insider now directly owns 42,907 shares of the company’s stock. Based on the current stock price, these shares are worth $2,511,775.78. The Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC.
Additionally, on Monday, December 19, Cedric Francois, the company’s Chief Executive Officer, sold 28,200 shares of the company’s stock. The purchase of each share occurred at an average price of $52.06, bringing the total value of the transaction to $1,468,092.00. The sale was conducted. The transaction resulted in the company’s CEO acquiring ownership of 965,128 shares, valued at approximately $50,244,563.68. Disclosures that are related to the sale might be found in this section of the website. According to the most recent financial filings, company insiders made a total profit of $4,309,345 from the sale of 86,450 shares of company stock over the most recent three months. Employed employees own 8.0% of the company’s total shares.
Apellis Pharmaceuticals, Inc., a biopharmaceutical company currently in the development stage of commercialization, is focusing on the discovery, development, and commercialization of therapeutic molecules that suppress the complement system to treat autoimmune and inflammatory conditions. The company is currently in the development stage of commercialization. Pegcetacoplan, the leading product candidate for the company, is currently the focus of clinical trials in Phase III for the treatment of geographic atrophy (GA). This condition is linked to age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH).